- Home
- BCLI vs ABVC Comparison
BCLI vs ABVC Comparison
Compare BCLI & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- ABVC
- Stock Information
- Founded
- BCLI 2000
- ABVC 2015
- Country
- BCLI United States
- ABVC United States
- Employees
- BCLI N/A
- ABVC N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- ABVC Health Care
- Exchange
- BCLI Nasdaq
- ABVC Nasdaq
- Market Cap
- BCLI 13.5M
- ABVC 12.8M
- IPO Year
- BCLI N/A
- ABVC N/A
- Fundamental
- Price
- BCLI $1.89
- ABVC $0.54
- Analyst Decision
- BCLI Strong Buy
- ABVC
- Analyst Count
- BCLI 1
- ABVC 0
- Target Price
- BCLI $30.00
- ABVC N/A
- AVG Volume (30 Days)
- BCLI 109.6K
- ABVC 150.8K
- Earning Date
- BCLI 11-14-2024
- ABVC 03-12-2025
- Dividend Yield
- BCLI N/A
- ABVC N/A
- EPS Growth
- BCLI N/A
- ABVC N/A
- EPS
- BCLI N/A
- ABVC N/A
- Revenue
- BCLI N/A
- ABVC $509,788.00
- Revenue This Year
- BCLI N/A
- ABVC N/A
- Revenue Next Year
- BCLI N/A
- ABVC N/A
- P/E Ratio
- BCLI N/A
- ABVC N/A
- Revenue Growth
- BCLI N/A
- ABVC N/A
- 52 Week Low
- BCLI $1.05
- ABVC $0.41
- 52 Week High
- BCLI $11.85
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- BCLI 44.80
- ABVC 47.67
- Support Level
- BCLI $1.90
- ABVC $0.50
- Resistance Level
- BCLI $2.17
- ABVC $0.58
- Average True Range (ATR)
- BCLI 0.18
- ABVC 0.06
- MACD
- BCLI -0.05
- ABVC -0.01
- Stochastic Oscillator
- BCLI 4.76
- ABVC 20.63
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.